Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8570463 | 1.00 | GAA (0.40) | GAAHCRTR2MALT1EPHX1NPSR1 | |
| SCHEMBL6175782 | 1.00 | GAA (0.40) | GAAHCRTR2MALT1EPHX1NPSR1 | |
| SCHEMBL27410738 | 0.79 | FUCA1 (0.42) | MALT1MKNK2 | |
| SCHEMBL35211069 | 0.79 | FUCA1 (0.42) | MALT1MKNK2 | |
| SCHEMBL12506986 | 0.79 | FUCA1 (0.42) | MALT1MKNK2 | |
| SCHEMBL1398833 | 0.79 | EPHX1 (0.44) | GAAEPHX1NPSR1TDP1MEN1 | |
| SCHEMBL25617413 | 0.79 | EPHX1 (0.44) | GAAEPHX1NPSR1TDP1MEN1 | |
| SCHEMBL18992238 | 0.79 | EPHX1 (0.44) | GAAEPHX1NPSR1TDP1MEN1 | |
| SCHEMBL3255850 | 0.78 | TDP1 (0.43) | GAAHCRTR2EPHX1NPSR1TDP1 | |
| SCHEMBL30758977 | 0.78 | HCRTR2 (0.38) | GAAHCRTR2EPHX1NPSR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072451-A1 | RAS-PI3K INHIBITORS FOR THE TREATMENT OF CANCER AND IMMUNOLOGICAL DISEASES | VIVIDION THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-12-28 | — | — | US | disclosed |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2023-09-07 | — | — | US | disclosed |
| US-11299473-B2 | Benzimidazole and indole compounds and uses thereof | INCYTE CORPORATION (US) | 2022-04-12 | — | — | US | disclosed |
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | EPIZYME INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-04-28 | — | — | US | disclosed |
| WO-2020016434-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | OSPEDALE SAN RAFFAELE S.R.L. (IT) | 2020-01-23 | — | — | WO | disclosed |
| EP-3597653-A1 | CYCLIC INHIBITORS OF HEPATITIS B VIRUS | IRBM S.P.A. (IT) | 2020-01-22 | — | — | EP | disclosed |
| US-20190315717-A1 | BENZIMIDAZOLE AND INDOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-10-17 | — | — | US | disclosed |
| US-9738651-B2 | CARM1 inhibitors and uses thereof | Epizyme, Inc. (US) | 2017-08-22 | — | — | US | disclosed |
| WO-2016044641-A2 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-02-11 | — | — | US | disclosed |
| EP-2970219-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014144169-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-6943160-B2 | Morpholine derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2005-09-13 | — | — | US | disclosed |
| EP-1353918-B1 | MORPHOLINE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-01-12 | — | — | EP | disclosed |
| US-20040058921-A1 | Morpholine derivatives as antagonists of orexin receptors | SMITHKLINE BEECHAM PLC (GB) | 2004-03-25 | — | — | US | disclosed |
| EP-1255739-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001053273-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299473-B2 | Benzimidazole and indole compounds and uses thereof | PGK1, PDXK, HIPK1 | GAA 1096/4885HCRTR2 4105/4885MALT1 1882/4885 |
| US-20190315717-A1 | BENZIMIDAZOLE AND INDOLE COMPOUNDS AND USES THEREOF | PGK1, PDXK, HIPK1 | GAA 1096/4885HCRTR2 4105/4885MALT1 1882/4885 |
| US-20210155631-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | GAA 2130/4885HCRTR2 3427/4885MALT1 426/4885 |
| US-20230279020-A9 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | GAA 2130/4885HCRTR2 3427/4885MALT1 426/4885 |
| US-11834455-B2 | Carm1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | GAA 2153/4885HCRTR2 3467/4885MALT1 425/4885 |
| US-10633389-B2 | CARM1 inhibitors and uses thereof | CARM1, TIAM1, ADRM1 | GAA 2130/4885HCRTR2 3427/4885MALT1 426/4885 |
| US-20040058921-A1 | Morpholine derivatives as antagonists of orexin receptors | HCRTR2, HCRTR1, OXTR | GAA 3709/4885HCRTR2 1/4885MALT1 4092/4885 |
| US-20230416263-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | GAA 2130/4885HCRTR2 3427/4885MALT1 426/4885 |
| US-20160039834-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, TIAM1, ADRM1 | GAA 1957/4885HCRTR2 3639/4885MALT1 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.